Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
The Andean wonder drug : cinchona bark and imperial science in the Spanish Atlantic, 1630-1800 / / Matthew James Crawford
| The Andean wonder drug : cinchona bark and imperial science in the Spanish Atlantic, 1630-1800 / / Matthew James Crawford |
| Autore | Crawford Matthew James |
| Pubbl/distr/stampa | Pittsburgh, Pennsylvania : , : University of Pittsburgh Press, , 2016 |
| Descrizione fisica | 1 online resource (297 p.) |
| Disciplina | 615.1 |
| Soggetto topico |
Cinchona bark - Therapeutic use
Drugs - History Medicine - History Science - Social aspects |
| Soggetto genere / forma | Electronic books. |
| ISBN | 0-8229-8139-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Acknowledgements; Introduction: The Power and Fragility of European Science in the Spanish Atlantic World; Part I. Andean, Atlantic, and Imperial Networks of Knowledge; 1. Quina as a Medicament from the Andean World; 2. Quina as a Product of the Atlantic World; 3. Quina as a Natural Resource for the Spanish Empire; Part II. The Rule of the Local and the Rise of the Botanists; 4. Loja's Bark Collectors, the King's Pharmacists, and the Search for the Best Bark; 5. Botanists as the Empire's New Experts in Madrid
6. Imperial Reform, Local Knowledge, and the Limits of Botany in the Andean World7. Regalist and Mercantilist Visions of Empire in the "War of the Quinas"; Conclusion: The Natures of Empire before the "Drapery" of Modern Science; Notes; Bibliography; Index |
| Record Nr. | UNINA-9910466442203321 |
Crawford Matthew James
|
||
| Pittsburgh, Pennsylvania : , : University of Pittsburgh Press, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Andean wonder drug : cinchona bark and imperial science in the Spanish Atlantic, 1630-1800 / / Matthew James Crawford
| The Andean wonder drug : cinchona bark and imperial science in the Spanish Atlantic, 1630-1800 / / Matthew James Crawford |
| Autore | Crawford Matthew James |
| Pubbl/distr/stampa | Pittsburgh, Pennsylvania : , : University of Pittsburgh Press, , 2016 |
| Descrizione fisica | 1 online resource (297 p.) |
| Disciplina | 615.1 |
| Soggetto topico |
Cinchona bark - Therapeutic use
Drugs - History Medicine - History Science - Social aspects |
| ISBN | 0-8229-8139-4 |
| Classificazione | SCI034000 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Acknowledgements; Introduction: The Power and Fragility of European Science in the Spanish Atlantic World; Part I. Andean, Atlantic, and Imperial Networks of Knowledge; 1. Quina as a Medicament from the Andean World; 2. Quina as a Product of the Atlantic World; 3. Quina as a Natural Resource for the Spanish Empire; Part II. The Rule of the Local and the Rise of the Botanists; 4. Loja's Bark Collectors, the King's Pharmacists, and the Search for the Best Bark; 5. Botanists as the Empire's New Experts in Madrid
6. Imperial Reform, Local Knowledge, and the Limits of Botany in the Andean World7. Regalist and Mercantilist Visions of Empire in the "War of the Quinas"; Conclusion: The Natures of Empire before the "Drapery" of Modern Science; Notes; Bibliography; Index |
| Record Nr. | UNINA-9910796325203321 |
|
Crawford Matthew James
|
||
| Pittsburgh, Pennsylvania : , : University of Pittsburgh Press, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Andean wonder drug : cinchona bark and imperial science in the Spanish Atlantic, 1630-1800 / / Matthew James Crawford
| The Andean wonder drug : cinchona bark and imperial science in the Spanish Atlantic, 1630-1800 / / Matthew James Crawford |
| Autore | Crawford Matthew James |
| Pubbl/distr/stampa | Pittsburgh, Pennsylvania : , : University of Pittsburgh Press, , 2016 |
| Descrizione fisica | 1 online resource (297 p.) |
| Disciplina | 615.1 |
| Soggetto topico |
Cinchona bark - Therapeutic use
Drugs - History Medicine - History Science - Social aspects |
| ISBN | 0-8229-8139-4 |
| Classificazione | SCI034000 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Acknowledgements; Introduction: The Power and Fragility of European Science in the Spanish Atlantic World; Part I. Andean, Atlantic, and Imperial Networks of Knowledge; 1. Quina as a Medicament from the Andean World; 2. Quina as a Product of the Atlantic World; 3. Quina as a Natural Resource for the Spanish Empire; Part II. The Rule of the Local and the Rise of the Botanists; 4. Loja's Bark Collectors, the King's Pharmacists, and the Search for the Best Bark; 5. Botanists as the Empire's New Experts in Madrid
6. Imperial Reform, Local Knowledge, and the Limits of Botany in the Andean World7. Regalist and Mercantilist Visions of Empire in the "War of the Quinas"; Conclusion: The Natures of Empire before the "Drapery" of Modern Science; Notes; Bibliography; Index |
| Record Nr. | UNINA-9910812989803321 |
|
Crawford Matthew James
|
||
| Pittsburgh, Pennsylvania : , : University of Pittsburgh Press, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Life saving drugs [[electronic resource] ] : the elusive magic bullet / / John Mann
| Life saving drugs [[electronic resource] ] : the elusive magic bullet / / John Mann |
| Autore | Mann J |
| Pubbl/distr/stampa | Cambridge, U.K., : Royal Society of Chemistry, c2004 |
| Descrizione fisica | 1 online resource (257 p.) |
| Disciplina | 615.109 |
| Collana | RSC paperbacks |
| Soggetto topico |
Drugs - Research - History
Pharmacology - History Drugs - History |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-84755-122-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Life Saving DrugsOFC; LSD_Pre-i-viii; LSD_Ch01_001_010; LSD_Ch02_011_084; LSD_Ch03_085_140; LSD_Ch04_141_222; LSD_Ch05_223_232; LSD_Further reading_233_240; LSD_Subject Index_241_248 |
| Record Nr. | UNINA-9910455222203321 |
|
Mann J
|
||
| Cambridge, U.K., : Royal Society of Chemistry, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Life saving drugs [[electronic resource] ] : the elusive magic bullet / / John Mann
| Life saving drugs [[electronic resource] ] : the elusive magic bullet / / John Mann |
| Autore | Mann J |
| Pubbl/distr/stampa | Cambridge, U.K., : Royal Society of Chemistry, c2004 |
| Descrizione fisica | 1 online resource (257 p.) |
| Disciplina | 615.109 |
| Collana | RSC paperbacks |
| Soggetto topico |
Drugs - Research - History
Pharmacology - History Drugs - History |
| ISBN | 1-84755-122-X |
| Classificazione | 44.42 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Life Saving DrugsOFC; LSD_Pre-i-viii; LSD_Ch01_001_010; LSD_Ch02_011_084; LSD_Ch03_085_140; LSD_Ch04_141_222; LSD_Ch05_223_232; LSD_Further reading_233_240; LSD_Subject Index_241_248 |
| Record Nr. | UNINA-9910778311103321 |
|
Mann J
|
||
| Cambridge, U.K., : Royal Society of Chemistry, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Top drugs : history, pharmacology, syntheses / / Jie Jack Li
| Top drugs : history, pharmacology, syntheses / / Jie Jack Li |
| Autore | Li Jie Jack |
| Pubbl/distr/stampa | New York, New York : , : Oxford University Press, , 2015 |
| Descrizione fisica | 1 online resource (219 p.) |
| Disciplina | 615.1 |
| Collana | Oxford scholarship online |
| Soggetto topico |
Drugs - History
Drugs - Design Pharmaceutical chemistry |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-19-756291-4
0-19-936260-2 0-19-936259-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Top Drugs History, Pharmacology, and Syntheses; Copyright; Dedication; Contents; Preface; Cardiovascular Drugs; Chapter 1: Atorvastatin Calcium (Lipitor); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 2: Clopidogrel Bisulfate (Plavix); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Bioavailability, Metabolism, and Toxicology; 2.2 Mechanism of Action; 2.3 Structure-Activity Relationship; 3 SYNTHESIS
3.1 Discovery Route3.2 Process Route; 3.3 Synthesis of Radio-labeled API; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 3: Amlodipine (Novasc); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Cancer Drugs; Chapter 4: Paclitaxel (Taxol); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 PROCESS SEMI-SYNTHESIS; 4 TOTAL SYNTHESIS 4.1 Holton's Synthesis4.2 Nicolaou's Synthesis; 4.3 Danishefsky's Synthesis; 4.4 Wender's Synthesis; 5 CONCLUDING REMARKS; 6 REFERENCES; Chapter 5: Imatinib Mesylate (Gleevec); 1 HISTORY; 1.1 A Brief History of Cancer Drugs; 1.2 Treatments of Chronic Myeloid Leukemia; 1.3 Protein Kinase Inhibitors; 1.4 Genesis of Gleevec; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; Drugs for Metabolic Diseases Chapter 6: Sitagliptin (Januvia)1 HISTORY OF DIABETES AND DIABETIC DRUGS; 1.1 Sulfonylureas; 1.2. Biguanides; 1.3 PPARγ Agonists ; 2 PHARMACOLOGY; 2.1 Mechanism of Action ; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESES; 3.1 Discovery Synthesis; 3.2 Process/Manufacturing Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; CNS Drugs; Chapter 7: Duloxetine Hydrochloride (Cymbalta) ; 1 HISTORY OF DEPRESSION AND ANTIDEPRESSANTS; 1.1 Monoamine Oxidase Inhibitors; 1.2 Tricyclic Antidepressants; 1.3 Selective Serotonin Reuptake Inhibitors 1.4 Serotonin and Norepinephrine Reuptake Inhibitors2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology ; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 8: Olanzapine (Zyprexa) ; 1 HISTORY OF SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUGS ; 1.1 Typical Antipsychotics-The First Generation; 1.2 Atypical Antipsychotics-The Second Generation; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS 3.1 Discovery Route |
| Record Nr. | UNINA-9910460278403321 |
|
Li Jie Jack
|
||
| New York, New York : , : Oxford University Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Top drugs : history, pharmacology, syntheses / / Jie Jack Li
| Top drugs : history, pharmacology, syntheses / / Jie Jack Li |
| Autore | Li Jie Jack |
| Pubbl/distr/stampa | New York, New York : , : Oxford University Press, , 2015 |
| Descrizione fisica | 1 online resource (219 p.) |
| Disciplina | 615.1 |
| Collana | Oxford scholarship online |
| Soggetto topico |
Drugs - History
Drugs - Design Pharmaceutical chemistry |
| ISBN |
0-19-756291-4
0-19-936260-2 0-19-936259-9 |
| Classificazione | MED071000SCI013060 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Top Drugs History, Pharmacology, and Syntheses; Copyright; Dedication; Contents; Preface; Cardiovascular Drugs; Chapter 1: Atorvastatin Calcium (Lipitor); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 2: Clopidogrel Bisulfate (Plavix); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Bioavailability, Metabolism, and Toxicology; 2.2 Mechanism of Action; 2.3 Structure-Activity Relationship; 3 SYNTHESIS
3.1 Discovery Route3.2 Process Route; 3.3 Synthesis of Radio-labeled API; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 3: Amlodipine (Novasc); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Cancer Drugs; Chapter 4: Paclitaxel (Taxol); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 PROCESS SEMI-SYNTHESIS; 4 TOTAL SYNTHESIS 4.1 Holton's Synthesis4.2 Nicolaou's Synthesis; 4.3 Danishefsky's Synthesis; 4.4 Wender's Synthesis; 5 CONCLUDING REMARKS; 6 REFERENCES; Chapter 5: Imatinib Mesylate (Gleevec); 1 HISTORY; 1.1 A Brief History of Cancer Drugs; 1.2 Treatments of Chronic Myeloid Leukemia; 1.3 Protein Kinase Inhibitors; 1.4 Genesis of Gleevec; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; Drugs for Metabolic Diseases Chapter 6: Sitagliptin (Januvia)1 HISTORY OF DIABETES AND DIABETIC DRUGS; 1.1 Sulfonylureas; 1.2. Biguanides; 1.3 PPARγ Agonists ; 2 PHARMACOLOGY; 2.1 Mechanism of Action ; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESES; 3.1 Discovery Synthesis; 3.2 Process/Manufacturing Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; CNS Drugs; Chapter 7: Duloxetine Hydrochloride (Cymbalta) ; 1 HISTORY OF DEPRESSION AND ANTIDEPRESSANTS; 1.1 Monoamine Oxidase Inhibitors; 1.2 Tricyclic Antidepressants; 1.3 Selective Serotonin Reuptake Inhibitors 1.4 Serotonin and Norepinephrine Reuptake Inhibitors2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology ; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 8: Olanzapine (Zyprexa) ; 1 HISTORY OF SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUGS ; 1.1 Typical Antipsychotics-The First Generation; 1.2 Atypical Antipsychotics-The Second Generation; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS 3.1 Discovery Route |
| Record Nr. | UNINA-9910797122703321 |
|
Li Jie Jack
|
||
| New York, New York : , : Oxford University Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Top drugs : history, pharmacology, syntheses / / Jie Jack Li
| Top drugs : history, pharmacology, syntheses / / Jie Jack Li |
| Autore | Li Jie Jack |
| Pubbl/distr/stampa | New York, New York : , : Oxford University Press, , 2015 |
| Descrizione fisica | 1 online resource (219 p.) |
| Disciplina | 615.1 |
| Collana | Oxford scholarship online |
| Soggetto topico |
Drugs - History
Drugs - Design Pharmaceutical chemistry |
| ISBN |
0-19-756291-4
0-19-936260-2 0-19-936259-9 |
| Classificazione | MED071000SCI013060 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Top Drugs History, Pharmacology, and Syntheses; Copyright; Dedication; Contents; Preface; Cardiovascular Drugs; Chapter 1: Atorvastatin Calcium (Lipitor); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 2: Clopidogrel Bisulfate (Plavix); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Bioavailability, Metabolism, and Toxicology; 2.2 Mechanism of Action; 2.3 Structure-Activity Relationship; 3 SYNTHESIS
3.1 Discovery Route3.2 Process Route; 3.3 Synthesis of Radio-labeled API; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 3: Amlodipine (Novasc); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Cancer Drugs; Chapter 4: Paclitaxel (Taxol); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 PROCESS SEMI-SYNTHESIS; 4 TOTAL SYNTHESIS 4.1 Holton's Synthesis4.2 Nicolaou's Synthesis; 4.3 Danishefsky's Synthesis; 4.4 Wender's Synthesis; 5 CONCLUDING REMARKS; 6 REFERENCES; Chapter 5: Imatinib Mesylate (Gleevec); 1 HISTORY; 1.1 A Brief History of Cancer Drugs; 1.2 Treatments of Chronic Myeloid Leukemia; 1.3 Protein Kinase Inhibitors; 1.4 Genesis of Gleevec; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; Drugs for Metabolic Diseases Chapter 6: Sitagliptin (Januvia)1 HISTORY OF DIABETES AND DIABETIC DRUGS; 1.1 Sulfonylureas; 1.2. Biguanides; 1.3 PPARγ Agonists ; 2 PHARMACOLOGY; 2.1 Mechanism of Action ; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESES; 3.1 Discovery Synthesis; 3.2 Process/Manufacturing Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; CNS Drugs; Chapter 7: Duloxetine Hydrochloride (Cymbalta) ; 1 HISTORY OF DEPRESSION AND ANTIDEPRESSANTS; 1.1 Monoamine Oxidase Inhibitors; 1.2 Tricyclic Antidepressants; 1.3 Selective Serotonin Reuptake Inhibitors 1.4 Serotonin and Norepinephrine Reuptake Inhibitors2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology ; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 8: Olanzapine (Zyprexa) ; 1 HISTORY OF SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUGS ; 1.1 Typical Antipsychotics-The First Generation; 1.2 Atypical Antipsychotics-The Second Generation; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS 3.1 Discovery Route |
| Record Nr. | UNINA-9910826031703321 |
|
Li Jie Jack
|
||
| New York, New York : , : Oxford University Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
